Navigation Links
Pediatric Dengue Vaccine Initiative and Hawaii Biotech Partner Against Dengue Fever

The Pediatric Dengue Vaccine Initiative (PDVI), a program of the International Vaccine Institute (IVI), and Hawaii Biotech // , announced today their partnership to help develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria.

Dengue fever is a mosquito-borne disease to which over 2 billion people are exposed and which leads to infection in up to 100 million people every year, primarily children. Dengue infection results in about 20,000 deaths from dengue hemorrhagic fever and dengue shock syndrome, the most severe forms of the disease, according to estimates from the World Health Organization (WHO)*.

"Our primary objective is to ensure rapid introduction of Dengue vaccines into immunization programs in all affected areas as soon as a vaccine becomes available. Working with Hawaii Biotech puts us in collaboration with one of the leading companies concerned with this important disease” said Harold Margolis, Director of the PDVI. "

Dengue is a mosquito transmitted disease and occurs mostly in urban areas of Latin American and Asia with an unknown level in Africa. The disease causes substantial illness and significant economic costs for hospitalizations and treatment. Efforts to control the mosquitoes are expensive, of varying success, and difficult to sustain.

The IVI, based in Seoul, Korea, is the world’s only International Organization solely dedicated to vaccine research and development.

“The IVI has grown rapidly in its short life and we are enthusiastic about this close association with Hawaii Biotech. We believe this partnership will greatly accelerate our work to reduce the burden of dengue in developing countries” said Dr. John Clemens, Director General of IVI.

Hawaii Biotech has a long involvement in development of dengue vaccines and is the only company pursuing a novel approach that relies on p roduction of virus components through genetic technologies. Vaccines made with this modern technology are known for being very safe and effective.

“Hawaii Biotech’s state-of-the-art vaccine protein manufacturing process is ideal to address emerging and re-emerging infectious diseases at their origin in developing countries. We’re delighted to enter into this partnership with PDVI, and appreciate their recognition of our R&D program’s excellence and promise”, commented Leonard Firestone, MD, President and Chief Executive Officer.

Source-Newswis
SRM
'"/>




Related medicine news :

1. Support Services found to Dramatically Impact Pediatric Health Care
2. Pediatricians differ in their opinion of child abuse
3. New Treatment Discovered For Pediatric Cholera
4. Pediatricians Need To Talk To Parents Of Overweight Kids
5. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
6. FDA Accords Priority Review For Pediatric Crohns Disease Drug
7. WHO Updates Outdated Pediatric Growth Charts
8. Pediatricians Resignations Cause Concern at Sale
9. Mental Health Providers Can Be Successfully Located With Pediatricians
10. World’s First Pediatric Laparoscopic Liver Surger
11. Pediatric Dental Care Found Wanting
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine ... focus on preventative care with all my patients to alleviate possible future issues. I am ... to contact my office and my trained staff will assist you in any way possible.” ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology: